Literature DB >> 24692578

Incidence of bowel perforation in gastrointestinal lymphomas by location and histology.

R Vaidya1, T E Witzig2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24692578      PMCID： PMC4110448          DOI： 10.1093/annonc/mdu135

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Chemotherapy for primary gastric lymphoma: does in-patient observation prevent complications?

Authors:  N Maisey; A Norman; Y Prior; D Cunningham
Journal:  Clin Oncol (R Coll Radiol)       Date:  2004-02       Impact factor: 4.126

2.  Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92.

Authors:  P Koch; F del Valle; W E Berdel; N A Willich; B Reers; W Hiddemann; B Grothaus-Pinke; G Reinartz; J Brockmann; A Temmesfeld; R Schmitz; C Rübe; A Probst; G Jaenke; H Bodenstein; A Junker; C Pott; J Schultze; A Heinecke; R Parwaresch; M Tiemann
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

3.  Bowel perforation in intestinal lymphoma: incidence and clinical features.

Authors:  R Vaidya; T M Habermann; J H Donohue; K M Ristow; M J Maurer; W R Macon; J P Colgan; D J Inwards; S M Ansell; L F Porrata; I N Micallef; P B Johnston; S N Markovic; C A Thompson; G S Nowakowski; T E Witzig
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976
  3 in total
  2 in total

1.  Chidamide based combination regimen for treatment of monomorphic epitheliotropic intestinal T cell lymphoma following radical operation: Two case reports.

Authors:  Ting-Zhi Liu; Yi-Jia Zheng; Zhan-Wen Zhang; Shan-Shan Li; Jiao-Ting Chen; Ai-Hua Peng; Ren-Wei Huang
Journal:  World J Clin Cases       Date:  2020-04-06       Impact factor: 1.337

2.  Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Yongxian Hu; Jiasheng Wang; Chengfei Pu; Kui Zhao; Qu Cui; Guoqing Wei; Wenjun Wu; Lei Xiao; Yang Xiao; Jinping Wang; Zhao Wu; He Huang
Journal:  Cancer Res Treat       Date:  2018-02-05       Impact factor: 4.679
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.